2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 846

Rheumatoid Arthritis, Anti-Tumor Necrosis Factor Therapy, and Risk of Squamous Cell and Basal Cell Skin Cancer- a Nationwide Population Based Prospective Cohort Study from Sweden
Abstract Number: 1904

Rheumatoid Factor Isotype Testing to Identify Individuals in the Preclinical Period of Rheumatoid Arthritis
Abstract Number: 447

Rheumatoid Factor Isotypes in Relation to Antibodies Against Citrullinated Peptides in Individuals before Onset of Rheumatoid Arthritis
Abstract Number: 1560

Rheumatoid Factor Status Is a Predictor of Osteoporosis in Patients with Psoriatic Arthritis
Abstract Number: 1054

Rheumatoid Factor, Not ACPA, Is Associated with Disease Activity in Rheumatoid Arthritis
Abstract Number: 1361

Rheumatologists’ Attitudes on Cardiovascular Risk and Lipid Screening in Patients with Rheumatoid Arthritis at an Academic Medical Center
Abstract Number: 103

Rheumatology e-Consult Services: a Rheumatology Workforce Management Model
Abstract Number: 1985

Rheumatology Learning Management System
Abstract Number: 2883

Rheumatology-Specific Milestones for a Musculoskeletal Radiology Curriculum
Abstract Number: 781

Rho Kinase (ROCK) Activity in Aortitis: Comparison of Giant Cell Arteritis (GCA), Takayasu Arteritis (TA) and Isolated Aortitis (IA)
Abstract Number: 350

Rho-Associated Protein Kinase (ROCK) Activity Is Elevated in Rheumatoid Arthritis (RA) Patients and May be Responsive to RA Therapies
Abstract Number: 740

Right Ventricular Diastolic Impairment Is Common in Systemic Sclerosis and Is a Marker of Several Organ-Target Damage of the Disease
Abstract Number: 475

Risk Analysis of a First Adverse Event and Recurrent Infections during Biological Therapy in Chronic Inflammatory Arthritis
Abstract Number: 862

Risk Factors for Changes in Subclinical Atherosclerosis As Measured By Carotid Intima Media Thickness (IMT) and Plaque over 5 Years in Women with Systemic Lupus Erythematosus (SLE)
Abstract Number: 223

Risk Factors for Clinical Vertebral Fractures in Japanese Men and Women with Rheumatoid Arthritis: Results from a Large Prospective Observational Cohort Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].